nt 13

NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

NT 13 acetate is a partial agonist of NMDA receptor and can be used for research on depression, anxiety, and other related diseases.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Antifungalagent 131 (compound A20) is an antifungal agent with a minimum inhibitory concentration (MIC) of 64 μg/mL. When used in combination with Fluconazole, it demonstrates exceptional antifungal potential.

Antifungalagent 132 (compound 25) is a selective and potent antifungal agent. It inhibits Cryptococcus neoformans May1 with a Ki value of 180 pM.

Antifungalagent 130 (Compound A7) is an orally active antifungal agent exhibiting significant inhibitory activity against Candida glabrata [MIC= 0.12 ng/mL] and Cryptococcus neoformans [MIC= 0.12 ng/mL]. It effectively disrupts fungal cell iron homeostasis and induces oxidative stress, leading to antifungal effects. Additionally, Antifungalagent 130 inhibits the formation of fungal virulence factors, such as biofilms, capsules, urease, and melanin. This compound shows strong antifungal properties, making it suitable for research on drug-resistant fungal infections.

Anti-MRSA agent 13 (Compound 9b) is an effective antimicrobial against methicillin-resistant Staphylococcus aureus (MRSA) with a minimal inhibitory concentration (MIC) of 0.5–2 μg/mL for clinically isolated strains. It exhibits excellent biocompatibility, stable plasma tolerance, and a low propensity for resistance. Anti-MRSA agent 13 disrupts the cell wall and membrane, reduces metabolic activity, induces oxidative damage, and impairs DNA function, leading to MRSA death through a multi-target synergistic mechanism.

Antifungalagent 134 (Compound B13) is an antifungal agent effective against Botrytis cinerea, Alternaria solani, Fusarium graminearum, Rhizoctonia solani, Colletotrichum orbiculare, and Alternaria alternata with EC50 values of 3.24, 1.89, 1.70, 0.36, 4.27, and 1.50 μg/mL, respectively. It disrupts the fungal cell membranes and mitochondria, leading to substantial accumulation of reactive oxygen species (ROS). Additionally, Antifungalagent 134 exhibits significant herbicidal activity on field weeds such as Amaranthus retroflexus L and Abutilon theophrasti Medicus, and is applicable in crop disease and field weed research.

Antifungalagent 133 (compound D2) is an orally active antifungal compound with an MIC80 value of 0.13 µg/mL against C. neoformans H99. It is suitable for research on cryptococcal meningitis.

Anticancer agent 13 is a compound derived from dicarboxylic acids and amines, developed for use as an anticancer agent.

Antifungal agent 13 demonstrates significant antifungal activity against Sclerotinia sclerotiorum, achieving an EC50 of 1.25 mg/L.

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Antibacterial agent 131 is a compound with antibacterial properties.

Antibacterial agent 132 showed antimicrobial activity against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) with MIC90 values of <0.06 μg/mL and 62.50 μg/mL, respectively. Antibacterial agent 132 inhibited aromatase enzyme with IC50 of 0.047 μM.

Antibacterial Agent 136 (Compound 3), an oxadiazolone antibiotic, exhibits high antibacterial potency against Methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) 50 value of 0.8 μM [1].

Antibacterial agent 138 exhibits superior efficacy against multi-drug resistant bacteria by inhibiting their protein synthesis and affecting bacterial cell walls [1].

Antibacterial agent 139 exhibits antibacterial activity specifically targeting Gram-positive bacteria, including resistant strains such as MRSA (anti-MRSA), VISA (anti-VISA), and LRSE (anti-LRSE). It operates by depolarizing the bacterial cell membrane [1].

Antibacterial Agent 135 (example 7) effectively inhibits various bacteria, including P. aeruginosa, A. baumannii, E. coli, and K. pneumoniae, with a minimum inhibitory concentration (MIC) greater than 64 μg/mL [1].

Compound Rh1 (Anticancer agent 132) acts as an inducer of apoptosis and autophagy, exhibiting both antitumor and antimetastatic activities. It also arrests the cell cycle and inhibits cell proliferation [1].

Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy. Additionally, it suppresses cell metastasis through the inhibition of EGFR expression, which is mediated by FAK-regulated integrin β1 [1].

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

Compound 6h (Anticancer Agent 139) exhibits potent anticancer activity, engaging in a π-cationic interaction with Lys352 of Tubulin and demonstrating high efficacy against SNB-19, OVCAR-8, and NCI-H460 with PGIs of 86.61, 85.26, and 75.99, respectively. Moreover, it shows moderate activity against a range of other cancer cell lines — HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 — with PGIs between 51.88 and 67.55 [1].

Anticancer agent 130 (compound 8d) significantly induces apoptosis in A549 cells [1].

Compound 4b (antitrypanosomal agent 13) is a potent antitrypanosomal with notable trypanocidal and cytotoxic activities, exhibiting GI50 values of 0.18 μM against T. brucei and 8.4 μM for HL-60 [1].